Oraqix and Macroangiopathy (expanded source)
There is no Macroangiopathy reported by people who take Oraqix yet. This review analyzes which people have Macroangiopathy with Oraqix. It is created by eHealthMe based on reports from FDA, and is updated regularly.
What to expect?
Personalized health information
On eHealthMe you can find out what patients like me (same gender, age) reported their drugs and conditions on FDA since 1977. Our tools are simple to use, anonymous and free. Start now >>>
On Dec, 13, 2017
No report is found.
How to use the study: print a copy of the study and bring it to your health teams to ensure drug risks and benefits are fully discussed and understood.
Subscribe to the study: get notified of updates to the study.
Do you have Macroangiopathy when taking Oraqix?
- Check symptoms - is macroangiopathy caused by a drug or a condition?
- Get alerts to symptoms - forecast your symptoms and get alerts
- Report the side effect - help people in need and in real time
- Ask a question - ask a question related to the study
- write a review - share your experience related to the study
- More tools...
Expand the study to include all drugs with the same ingredientsMacroangiopathy and drugs with ingredients of lidocaine; prilocaine.
Limit the study to reports from FDA onlyMacroangiopathy and Oraqix from FDA reports
Oraqix has active ingredients of lidocaine; prilocaine. (latest outcomes from Oraqix 30 users)
Macroangiopathy (a disease of the large blood vessels in which fat and blood clots build up and stick to the vessel walls, blocking the flow of blood) has been reported by people with high blood pressure, breast cancer, stroke, type 2 diabetes, prostate cancer (latest reports from 34 Macroangiopathy patients).